Frank Vinluan / medcitynews - Protego Biopharma’s lead program is a potential treatment for the rare disease light chain amyloidosis. The startup says the novel mechanism of its oral small molecule should have better outcomes than antibodies from AstraZeneca and Prothena that failed t…
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment
Saturday, December 6, 2025, 10:21 am / permalink 16661 / 2 stories in 3 months
Judge orders Leapfrog to remove safety grades for five Florida hospitals (22 hrs)
Daily multivitamin slows epigenetic aging in randomized COSMOS analysis (41 hrs)
White House briefing triggered rapid drops in acetaminophen use in ERs (2 days)
NorthFeed Inc.
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.